首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Posttherapeutic Cure Criteria in Chagas Disease: Conventional Serology followed by Supplementary Serological Parasitological and Molecular Tests
【2h】

Posttherapeutic Cure Criteria in Chagas Disease: Conventional Serology followed by Supplementary Serological Parasitological and Molecular Tests

机译:恰加斯病的治疗后治疗标准:常规血清学然后进行补充血清学寄生虫学和分子检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We performed a critical study of conventional serology, followed by supplementary serological, parasitological, and molecular tests, to assess the response to etiologic treatment of Chagas' disease. A group of 94 Chagas' disease patients treated with benznidazole at least 10 years earlier were evaluated from the laboratory and clinical points of view. When conventional serology (enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence [IIF], and indirect hemagglutination [IHA]) and classic criteria (consistent results with any two of the three tests) or more rigorous criteria (consistent results from the three tests) were used, 10.6% and 8.5% of patients were considered treated and cured (TC) by classic and rigorous criteria, respectively. Patients were then evaluated using supplementary (recombinant ELISA and Trypanosoma cruzi excreted-secreted antigen blotting [TESA-blot]), parasitological (hemoculture), and molecular (PCR) tests. The results of recombinant ELISA were similar to those with the rigorous criterion (three consistent test results). The TESA-blot group showed a higher percentage (21.3%) of negative results than the groups defined by either cure criterion. Hemoculture and PCR gave negative results for all treated and cured (TC) patients, regardless of the criterion used. Recombinant ELISA and TESA-blot tests showed negative results for 70% and 87.5% of the patients categorized as TC by the classic and three-test criteria, respectively. For patients with discordant conventional serology, the supplementary serological and molecular tests were the decisive factor in determining therapeutic failure. Clinical evaluation showed that 62.5% of TC patients presented with the indeterminate form of the disease. Additionally, treated patients with negative TESA-blot results should be reevaluated later with all methodologies used here to verify whether TESA-blot is a reliable way to determine early parasitological cure of Chagas' disease.
机译:我们对常规血清学进行了批判性研究,随后进行了补充血清学,寄生虫学和分子检测,以评估对南美锥虫病病因治疗的反应。从实验室和临床角度评估了94例至少10年前接受过苯并硝唑治疗的Chagas病患者。当采用常规血清学(酶联免疫吸附测定[ELISA],间接免疫荧光[IIF]和间接血细胞凝集[IHA])和经典标准(与这三个测试中的任何两个测试结果一致)或更严格的标准(三个测试的结果一致)时测试),分别按照经典和严格标准将10.6%和8.5%的患者视为已治愈和治愈(TC)。然后使用补充(重组ELISA和克氏锥虫分泌分泌抗原印迹法[TESA印迹]),寄生虫学(血液培养)和分子(PCR)测试对患者进行评估。重组ELISA的结果与具有严格标准的结果相似(三个一致的测试结果)。 TESA印迹组的阴性结果百分率(21.3%)高于任一治愈标准所定义的组。不论采用何种标准,血培养和PCR对所有治疗和治愈的(TC)患者均给出阴性结果。重组ELISA和TESA印迹测试分别对经典和三项测试标准分类为TC的患者分别显示70%和87.5%的阴性结果。对于常规血清学不一致的患者,补充血清学和分子学检查是确定治疗失败的决定性因素。临床评估表明,有62.5%的TC患者表现出该病的不确定形式。此外,TESA印迹结果阴性的已治疗患者应在以后使用此处使用的所有方法重新评估,以验证TESA印迹是否是确定南美锥虫病早期寄生虫病治愈的可靠方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号